Clinical trial
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not…
NCT00436852 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00436852 |
|---|---|
| Title | ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment |
| Official title | A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Disseminated Neuroblastoma, Recurrent Neuroblastoma |
| Intervention type | Drug, Procedure |
| Interventions | ABT-751, quality-of-life assessment |
| Enrollment | 92 |
| Start date | Jan 1, 2007 |
| Primary completion | Sep 1, 2010 |
| Completion | Mar 30, 2015 |
| First posted | Feb 19, 2007 |
| Last update posted | Jul 17, 2019 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: